Strattera contains atomoxetine as its active component. It is classified as a neurologic medication and is available in pill form in strengths of 10 mg, 18 mg, 25 mg, and 40 mg. In Hong Kong, Strattera is a prescription-only product regulated by the Department of Health under the Pharmacy and Poisons Ordinance.
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). By blocking the norepinephrine transporter, it increases the concentration of norepinephrine in synaptic clefts, especially in brain regions that regulate attention and impulse control. The enhanced norepinephrine signaling helps reduce the core symptoms of attention-deficit/hyperactivity disorder (ADHD).
Key pharmacologic points:
Strattera is FDA- and EMA-approved for the treatment of ADHD in children, adolescents, and adults. In Hong Kong, the same indication is recognized by the local regulatory authority. It is prescribed for patients who require a non-stimulant option, particularly when stimulant therapy is unsuitable or not tolerated.
Typical patient profile:
This article provides educational information about Strattera and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Atomoxetine may be combined with stimulants in certain cases, but the combination increases the risk of cardiovascular side effects and requires close supervision by a prescriber.
Take the missed dose as soon as you remember if it is still at least 6 hours before the next scheduled dose. Otherwise, skip the missed dose and resume the regular dosing schedule, adjusting the timing to align with local day-night cycles.
Rarely, patients report blurred vision or difficulty focusing. If visual disturbances persist, seek evaluation, as they could signal narrow-angle glaucoma, a contraindicated condition.
Strattera is a non-stimulant and has a lower abuse potential. Its onset of action is slower, and it does not produce the same immediate “focus boost” typical of stimulants. Both classes are effective, but individual response varies.
Routine liver function tests are advisable if the patient has pre-existing liver disease or develops symptoms suggestive of hepatic injury. Otherwise, standard monitoring focuses on blood pressure, heart rate, and mood.
Atomoxetine may cause mild changes in appetite, which can indirectly influence glucose control. Patients with diabetes should monitor blood sugar more closely when initiating therapy.
In Hong Kong, authentic Strattera pills bear the imprint “STRATTERA [Strength]” along with a specific batch number. If the appearance differs, confirm authenticity with a pharmacist.
Unused tablets should be discarded at a pharmacy’s drug-take-back program or according to local waste-management guidelines to prevent accidental ingestion.
Regulatory agencies generally require medical certification for individuals in safety-critical roles. Strattera’s side-effect profile (e.g., dizziness, visual changes) may necessitate temporary restriction until stability is confirmed.
The 40 mg tablet allows flexible dosing increments, especially for patients requiring gradual titration or those with lower body weight. Combining tablets of different strengths helps reach the prescribed total daily dose without excess tablets.
